CTOR

Citius Oncology Inc

Apr 06 • 04:00PM ET

0.6871

-0.0159 -2.26 %

Healthcare • Drug Manufacturers - Specialty & Generic • USA • NASD

Index	-	P/E	-	EPS (ttm)	-0.31	Insider Own	81.22%	Shs Outstand	84.80M	Perf Week	34.25%
Market Cap	60.66M	Forward P/E	1.76	EPS next Y	0.39	Insider Trans	0.00%	Shs Float	16.58M	Perf Month	-35.79%
Enterprise Value	57.16M	PEG	-	EPS next Q	-0.01	Inst Own	7.77%	Short Float	6.28%	Perf Quarter	-36.38%
Income	-23.64M	P/S	15.40	EPS this Y	52.94%	Inst Trans	0.69%	Short Ratio	3.65	Perf Half Y	-63.45%
Sales	3.94M	P/B	1.00	EPS next Y	343.75%	ROA	-23.58%	Short Interest	1.04M	Perf YTD	-31.29%
Book/sh	0.69	P/C	8.31	EPS next 5Y	-	ROE	-47.41%	52W High	6.19 -88.90%	Perf Year	-0.43%
Cash/sh	0.08	P/FCF	-	EPS past 3/5Y	- -309.67%	ROIC	-37.99%	52W Low	0.49 39.88%	Perf 3Y	-93.36%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	79.99%	Volatility	17.90% 11.87%	Perf 5Y	-
Dividend TTM	-	EV/Sales	14.51	EPS Y/Y TTM	-61.87%	Oper. Margin	-567.43%	ATR (14)	0.08	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	0.32	Sales Y/Y TTM	-	Profit Margin	-599.28%	RSI (14)	41.50	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	0.83	EPS Q/Q	32.01%	SMA20	-3.55%	Beta	3.42	Target Price	6.00
Payout	-	Debt/Eq	0.07	Sales Q/Q	-	SMA50	-28.11%	Rel Volume	0.31	Prev Close	0.70
Employees	-	LT Debt/Eq	0.07	Earnings	Feb 13 BMO	SMA200	-56.81%	Avg Volume	285.71K	Price	0.69
IPO	Dec 08, 2022	Option/Short	No / Yes	EPS/Sales Surpr.	- -9.81%	Trades		Volume	88,732	Change	-2.26%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-23-25	Upgrade	Maxim Group	Hold → Buy	$6
Nov-27-24	Initiated	Maxim Group	Buy	$3

Mar-31-26 09:11AM	Citius Oncology Provides Commercial Update on LYMPHIR Launch Highlighting Early Adoption and Expanding Clinical Development (PR Newswire) +25.74%
Mar-24-26 08:00AM	Citius Oncology to Participate in USCLC Annual Workshop 2026, Highlighting LYMPHIR in Discussions with Leading Cutaneous Lymphoma Experts (PR Newswire) -6.83%
Mar-10-26 08:47AM	Citius Oncology Announces Positive Topline Results from Investigator-Initiated Phase 1 Study of LYMPHIR in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic Cancers (PR Newswire)
Mar-04-26 09:15AM	Citius Oncology Announces Preliminary Topline Phase 1 Data from Study of LYMPHIR (E7777) Dosing Prior to Commercial CAR-T Therapy in High-Risk Diffuse Large B-Cell Lymphoma (PR Newswire)
Feb-24-26 09:35AM	Citius Oncology (CTOR) Expands LYMPHIR Distribution to Europe Through Exclusive Agreement With Uniphar (Insider Monkey)
08:00AM	Loading…
Feb-13-26 08:00AM	Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR (PR Newswire)
08:00AM	Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR (PR Newswire)
Feb-12-26 06:55AM	Citius Oncology and Uniphar sign European distribution deal for Lymphir (Pharmaceutical Business Review)
Feb-11-26 08:00AM	Citius Oncology Expands International Distribution of LYMPHIR to European Union Through Exclusive Agreement with Uniphar (PR Newswire)
Jan-07-26 10:32AM	How $594B in Precision Tech is Cracking the Metastatic Cancer Code (PR Newswire)
Dec-23-25 04:30PM	Citius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update (PR Newswire) -9.84%
Dec-10-25 04:30PM	Citius Oncology Announces Closing of $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules (PR Newswire)
Dec-09-25 08:30AM	Citius Oncology Announces $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules (PR Newswire) +6.42%
Dec-04-25 08:37AM	Citius Oncology Expands LYMPHIR Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-Kim (PR Newswire) -9.02%
Dec-01-25 12:00PM	Citius Oncology Announces U.S. Commercial Launch of LYMPHIR, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL) (PR Newswire) +19.71%
08:00AM	Loading…
Nov-25-25 08:00AM	Citius Oncology to Exhibit at the 67th American Society of Hematology (ASH) Annual Meeting (PR Newswire) +8.04%
Nov-21-25 08:37AM	Citius Oncology to Advance Commercial Launch of LYMPHIR with Verix AI Integration (PR Newswire)
Oct-21-25 08:19AM	Citius Oncology finalises McKesson deal for Lymphir distribution (Pharmaceutical Business Review)
Oct-20-25 08:37AM	Citius Oncology Signs U.S. Distribution Agreement with McKesson to Support LYMPHIR Commercial Launch (PR Newswire) +5.29%
Oct-17-25 05:00PM	Citius Pharmaceuticals and Citius Oncology to Participate in Upcoming October 2025 Conferences (PR Newswire) -5.03%
Oct-16-25 08:47AM	Citius Oncology Signs Exclusive Commercialization Agreement with EVERSANA to Support Planned Q4 2025 Launch of LYMPHIR (PR Newswire)
Oct-08-25 10:58AM	Breakthrough Discoveries Unlock $643B Cancer Treatment Market By 2034 (PR Newswire)
Oct-07-25 08:47AM	Citius Oncology Establishes International Access to LYMPHIR via Named Patient Programs in Southern Europe (PR Newswire)
Sep-10-25 04:30PM	Citius Oncology Announces Closing of $9.0 Million Registered Direct Offering and Concurrent Private Placement (PR Newswire)
Sep-09-25 08:30AM	Citius Oncology Announces Pricing of $9.0 Million Registered Direct Offering and Concurrent Private Placement (PR Newswire)
Aug-22-25 08:47AM	Citius Oncology Deploys AI Platform to Amplify the Performance of its Commercial Team Ahead of LYMPHIR Launch (PR Newswire) +7.36%
Aug-12-25 04:30PM	Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2025 Financial Results and Provides Business Update (PR Newswire) +5.92%
04:30PM	Citius Oncology, Inc. Reports Fiscal Third Quarter 2025 Financial Results and Provides Business Update (PR Newswire)
Aug-06-25 08:30AM	Clinical Progress in Rare Disease Signals Long-Term Revenue Potential for Innovators (PR Newswire) +5.52%
Jul-17-25 04:30PM	Citius Oncology Announces Closing of $9.0 Million Public Offering (PR Newswire)
09:15AM	Loading…
Jul-16-25 09:15AM	Citius Oncology Announces Pricing of $9.0 Million Public Offering (PR Newswire)
Jul-15-25 08:32AM	Citius Oncology Expands Distribution Network for LYMPHIR with Execution of Distribution Services Agreement with Cencora (PR Newswire) -20.62%
Jun-26-25 11:44AM	The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough? (PR Newswire) +26.81%
Jun-17-25 08:08AM	Citius Oncology Anticipates Commercial Launch of LYMPHIR in 2025 (PR Newswire)
Jun-12-25 09:00AM	After Major Oncology Conference, All Eyes Turn to Industry Innovation (PR Newswire)
Jun-09-25 08:37AM	Citius Oncology Enters into Distribution Services Agreement with Cardinal Health (PR Newswire) +17.13%
May-14-25 04:30PM	Citius Oncology, Inc. Reports Fiscal Second Quarter 2025 Financial Results and Provides Business Update (PR Newswire)
Feb-14-25 04:30PM	Citius Oncology, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update (PR Newswire) -5.60%
Feb-06-25 08:55AM	Citius Pharmaceuticals and Citius Oncology Announce Unique Permanent J-Code Issued for LYMPHIR by Centers for Medicare and Medicaid Services (PR Newswire) -5.56%
Jan-07-25 08:08AM	Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025 (PR Newswire) -11.69%
07:57AM	Citius Oncology to explore strategic alternatives (TipRanks)
Jan-06-25 07:50AM	Citius Oncology Engages Jefferies as Exclusive Financial Advisor to Explore Strategic Alternatives (PR Newswire) +18.46%
Dec-31-24 07:10AM	Citius Pharmaceuticals upgraded to Buy from Hold at D. Boral Capital (TipRanks)
Dec-27-24 05:00PM	Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update (PR Newswire) +8.33% +7.69%
05:00PM	Citius Oncology, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update (PR Newswire)
Nov-11-24 08:45AM	Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Promising Preliminary Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab (KEYTRUDA) and LYMPHIR in Cancer Patients with Recurrent Solid Tumors (PR Newswire) +6.30%
Sep-05-24 04:30PM	Citius Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference (PR Newswire) +8.38% -5.60%
08:30AM	Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce LYMPHIR (Denileukin Diftitox-cxdl) Added to National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (PR Newswire)

Citius Oncology, Inc. is a biopharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CTOR

Citius Oncology Inc

Upgrade your Finviz experience